ACADIA Pharmaceuticals Inc (ACAD)

Price $19.73 · -2.86% today · $3.4B market cap.

biotech_pharma

Strongest Overalllow risk← Back

Simulated history. Equities don't yet have ingested OHLCV, so the price chart and technical indicators below are illustrative (deterministic, labelled) — not real market history.

Price & Performance

$19.73 -28.7% over 1Y

Simulated history — illustrative, not real market data.

Today

-2.86%

1 week

-0.35%

1 month

-2.08%

1 year

-9.20%

Technical Analysis

RSI (14)

62.20

MACD

0.03

MACD signal

-0.12

MACD hist

0.15

SMA 20

18.88

SMA 50

19.22

EMA 20

19.01

ATR (14)

0.46

Support

18.07

Resistance

19.84

Bollinger upper

19.78

Bollinger lower

17.99

▹ RSI 62 — neutral
▹ MACD above signal (bullish)
▹ Price above 20/50-day averages

Indicators describe past price action — they do not predict future direction.

Fundamental Analysis

P/E ratio

8.93

Return on equity

32.39%

EBITDA

n/a

EPS (TTM)

2.21

Net debt

n/a

Net margin

33.42%

Gross margin

91.13%

Current ratio

3.39

Debt / Equity

0.00

Dividend yield

n/a

Operating margin

7.59%

Revenue growth (YoY)

47.00%

Risk Assessment

Ann. volatility

31.9%

Max drawdown

37.4%

Liquidity

Adequate market capitalization

Leverage

Debt/equity 0.0 (manageable)

Valuation

P/E 9×

Earnings

Earnings dates are not tracked in this release.

Concentration

Single-name equity — no diversification within the position.

Estimated annualized volatility 32% with a maximum drawdown of 37% over the available window.

Investment Thesis (generated summary)

ACADIA Pharmaceuticals Inc (ACAD) screens constructively on the current data, with an opportunity score of 75/100. The score reflects the available fundamental, technical, valuation and sentiment inputs — it is a research screen, not a forecast or a recommendation to trade.

Bullish case

Strong net margin (33%)
Revenue growing 47% y/y
Low P/E (9×)

Bearish case

Weak price momentum

Potential catalysts

Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38
Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40

Horizon: ~1–3 months for technical signals; 12+ months for fundamental quality.

Thesis invalidated if: Momentum reverses and price breaks below its 50-day average; Earnings or guidance disappoint relative to consensus; A sector-level drawdown outweighs stock-specific strength.

News Sentiment

Bullish 75%Neutral 25%Bearish 0%